Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.
Publication
, Journal Article
Guidon, AC; Juel, VC
Published in: Neurology
June 4, 2019
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
June 4, 2019
Volume
92
Issue
23
Start / End Page
1079 / 1080
Location
United States
Related Subject Headings
- Receptors, Cholinergic
- Neurology & Neurosurgery
- Myasthenia Gravis
- Humans
- Antibodies
- 3209 Neurosciences
- 3202 Clinical sciences
- 1702 Cognitive Sciences
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Guidon, A. C., & Juel, V. C. (2019). Efgartigimod: A novel antibody depletion therapy in myasthenia gravis. Neurology, 92(23), 1079–1080. https://doi.org/10.1212/WNL.0000000000007605
Guidon, Amanda C., and Vern C. Juel. “Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.” Neurology 92, no. 23 (June 4, 2019): 1079–80. https://doi.org/10.1212/WNL.0000000000007605.
Guidon AC, Juel VC. Efgartigimod: A novel antibody depletion therapy in myasthenia gravis. Neurology. 2019 Jun 4;92(23):1079–80.
Guidon, Amanda C., and Vern C. Juel. “Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.” Neurology, vol. 92, no. 23, June 2019, pp. 1079–80. Pubmed, doi:10.1212/WNL.0000000000007605.
Guidon AC, Juel VC. Efgartigimod: A novel antibody depletion therapy in myasthenia gravis. Neurology. 2019 Jun 4;92(23):1079–1080.
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
June 4, 2019
Volume
92
Issue
23
Start / End Page
1079 / 1080
Location
United States
Related Subject Headings
- Receptors, Cholinergic
- Neurology & Neurosurgery
- Myasthenia Gravis
- Humans
- Antibodies
- 3209 Neurosciences
- 3202 Clinical sciences
- 1702 Cognitive Sciences
- 1109 Neurosciences
- 1103 Clinical Sciences